Are we undertreating aortic regurgitation?

At EuroPCR 2025, Victoria Delgado, Helge Möllmann, and Dan Blackman gather to discuss a crucial but often under-addressed challenge in structural heart disease: the under-referral and under-treatment of patients with aortic regurgitation (AR).

The conversation begins with the diagnostic challenges surrounding severe AR, followed by a striking observation—only 25 to 30% of patients diagnosed with severe AR currently receive surgical aortic valve replacement. They emphasise the importance of differentiating between younger and older patients, since treatment strategies and outcomes may vary significantly across age groups.

New solutions are emerging. With dedicated transcatheter devices such as the JenaValve Trilogy System now available, the round table turns to recent clinical data and addresses an important question: how widely known—and accessible—are these new technologies in practice?

This discussion sheds light on the evolving landscape of AR treatment, and the importance of increasing both awareness and appropriate referrals for this complex patient population.

This interview was filmed at EuroPCR 2025: see more videos here.